MSI-H转移性结直肠癌免疫治疗后进展模式分型及生存差异
在212例dMMR/MSI-H转移性结直肠癌患者中,31%出现免疫检查点抑制剂治疗后进展,分为早期全面进展(52%)、晚期全面进展(28%)和寡进展(20%)。中位随访74.7个月,三组中位总生存分别为7.8、38.8和97.2个月(p<0.0001),提示需按进展模式制定个体化后续管理策略。
要点
- ICI治疗dMMR/MSI-H mCRC的进展可分为早期全面、晚期全面和寡进展三种模式
- 早期全面进展者中位OS不足1年(7.8个月),预后最差
- 寡进展占继发耐药的一半,中位OS达97.2个月,适合局部消融治疗
核心结论
- dMMR/MSI-H mCRC患者ICI治疗后进展呈现不同模式,早期全面进展者总生存不足1年。
- 寡进展占继发耐药的一半,与良好生存相关,为局部消融治疗提供机会。
研究设计与样本
- 前瞻性单中心ImmunoMSI队列(Saint-Antoine医院)中所有接受ICI治疗的dMMR/MSI-H mCRC患者,回顾性分析。
- 共纳入212例患者,65例(31%)出现进展,其中68%接受抗PD1单药、32%接受抗PD1联合抗CTLA4。
主要发现
- 早期全面进展34例(52%),晚期全面进展17例(28%),6个月后寡进展13例(20%)。
- 患者特征:右半肿瘤66%,既往原发灶手术82%,既往化疗86%,肝转移49%,腹膜转移25%,≥2个转移部位58%。
- 中位随访74.7个月,中位进展时间5.5个月;中位OS:早期全面进展7.8个月,晚期全面进展38.8个月,寡进展97.2个月(p<0.0001)。
- 寡进展者中9例接受局部治疗(手术、立体定向放疗或冷冻治疗),5例接受系统治疗,其中3例ICI再挑战。
关键数值与推荐
- 进展按iRECIST标准分类:早期全面进展(6个月内)、晚期全面进展(6个月后)、寡进展(6个月后且转移灶<3个,其他病灶控制)。
- 中位OS:早期全面进展7.8个月,晚期全面进展38.8个月,寡进展97.2个月(p<0.0001)。
临床怎么用
- 对ICI治疗后进展的dMMR/MSI-H mCRC患者应区分进展模式,早期全面进展者预后极差需积极调整治疗。
- 寡进展患者可考虑局部消融治疗(手术、立体定向放疗或冷冻治疗),部分患者可再挑战ICI。
局限性
- 单中心回顾性分析,样本量有限。
- 寡进展患者后续治疗异质性大,需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to assess patterns of progressive disease (PD) in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs). METHODS: All patients with ICI(s)-treated dMMR/MSI-H mCRC were included in the prospective, single-center ImmunoMSI cohort at Saint-Antoine Hospital and retrospectively analyzed. PD, per iRECIST criteria, was classified as early-global PD (within 6 months), late-global PD (after 6 months), or oligo-PD (limited to <3 metastases (after 6 months), with other lesions remaining controlled). Survival outcomes were analyzed. RESULTS: Among the 212 included patients, 65 (31 %) experienced PD (68 % received anti-PD1 monotherapy, 32 % anti-PD1 + anti-CTLA4). Early-global PD occurred in 34 patients (52 %), late-global PD in 17 (28 %), and oligo-PD after 6 months in 13 (20 %). Patient characteristics were right-sided tumor (66 %), prior primary tumor surgery (82 %), prior chemotherapy (86 %), liver metastasis (49 %), peritoneal carcinomatosis (25 %), and ≥ 2 metastatic sites (58 %). With a median follow-up of 74.7 months and a median time to progression of 5.5 months, median overall survival was 7.8 months for early-global PD, 38.8 months for late-global PD, and 97.2 months for oligo-PD (p < 0.0001). Among oligoprogressors, nine received local treatment (surgery, stereotaxic radiotherapy, or cryotherapy), while five received systemic therapy, including three rechallenged with ICIs. CONCLUSION: PD under ICI(s) in dMMR/MSI-H mCRC follows distinct patterns, with overall survival < 1 year in case of early-PD. Oligo-PD accounts for half of secondary resistance and is associated with favorable survival, offering an opportunity for focal ablative therapies, and highlighting the need for personalized post-progression management.
引用
- Cervantes B, Grosnon C, Samaille T, et al. Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management. Eur J Cancer. 2025. PMID: 41265146. doi:10.1016/j.ejca.2025.116119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。